Ouabain suppresses the growth and migration abilities of glioma U‑87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF‑1α.

Glioma is one of the most malignant forms of brain tumor, and has been of persistent concern due to its high recurrence and mortality rates, and limited therapeutic options. As a cardiac glycoside, ouabain has widespread applications in congestive heart diseases due to its positive cardiac inotropic effect by inhibiting Na+/K+‑ATPase. Previous studies have demonstrated that ouabain has antitumor activity in several types of human tumor, including glioma. However, the exact underlying mechanism remains to be elucidated. The purpose of present study was to elucidate the effect of ouabain on human glioma cell apoptosis and investigate the exact mechanism. U‑87MG cells were treated with various concentrations of ouabain for 24 h, following which cell viability and survival rate were assessed using a 3‑(4,5-dimethylthiazol-2‑yl)‑2,5‑diphenyltetrazolium bromide assay. The dynamic changes and cell motility were observed using digital holographic microscopy. Additionally, western blot analysis and high‑content screening assays were used to detect the protein expression levels of phosphorylated (p‑)Akt, mammalian target of rapamycin (mTOR), p‑mTOR and hypoxia‑inducible factor (HIF)‑1α, respectively. Compared with the control group, ouabain suppressed U‑87MG cell survival, and attenuated cell motility in a dose‑dependent manner (P<0.01). The downregulation of p‑Akt, mTOR, p‑mTOR and HIF‑1α were observed following treatment with 2.5 and 25 µmol/l of ouabain. These results suggested that ouabain exerted suppressive effects on tumor cell growth and motility, leading to cell death via regulating the intracellular Akt/mTOR signaling pathway and inhibiting the expression of HIF‑1α in glioma cells. The present study examined the mechanism underlying the antitumor property of ouabain, providing a novel potential therapeutic agent for glioma treatment.

Introduction

Gliomas are serious primary brain tumors, which account for 80% of malignant tumors of the central nervous system in the United States. Current therapeutic strategies for this type of brain cancer are inadequate and the median survival rate for patients with malignant glioma is 14 months due to their aggressive nature, high recurrence rate, and gradual increase in radiotherapy and chemotherapy resistance (1). Therefore, it is vital to examine the mechanisms underlying the progression of glioma and to urgently develop novel therapies with improved therapeutic effects for the treatment of patients with glioma.

Ouabain is a steroid, which is extracted from the seeds and leaves of digitalis (2). As a cardiac glycoside, ouabain is used in the treatment of congestive heart disease due to its positive cardiac inotropic effect by inhibiting Na+/K+-ATPase or Na+/K+ pumps and increasing intracellular calcium (3). Previous studies have shown that the plasma transporter, Na+/K+-ATPase, which is the unique receptor established for ouabain, not only functions as an ion pump, but is overexpressed in different types of tumor, including lung cancer, hepatoma and gliomas (4–6), and its inhibitors are concerned with the regulation of multiple intracellular signaling pathways, including Akt/mammalian target of rapamycin (mTOR), Ras and protein kinase C (PKC) (7).

Previous studies have reported that, as a specific Na+/K+-ATPase inhibitor, ouabain may affect the adhesion and metastasis of tumor cells, resulting in the apoptosis of several tumor cells, including malignant breast cancer, prostate cancer and human leukemia (8). In addition, epidemiological evidence shows that tumor patients treated with cardiac glycosides have lower mortality rates, compared with those treated without cardiac glycosides, suggesting that ouabain has potential antitumor effects (9). However, the mechanism underlying its antitumor effect remains to be elucidated.

In the present study, the human glioblastoma U-87MG cell line was selected to examine the effects of ouabain, as a specific Na+/K+-ATPase inhibitor, on the apoptosis of U87-MG cells, followed by preliminarily investigation of the role of the Akt/mTOR signaling pathway in the process.

Materials and methods

Materials

Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Ouabain was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from (Promega Corporation, Madison, WI, USA).

Cell culture and grouping

The human U-87MG glioma cell line was obtained from the American Type Culture Collection (Mannasas, VA, USA) and cultured in DMEM containing 10% FBS and 1% penicillin/streptomycin in a humidified incubator of 5% CO2 at 37°C. The cells were randomized into two groupings: Ouabain-treated groups (0.05, 0.25, 0.5, 2.5, 5 and 25 µmol/l for the MTT assay; 0.05, 0.5, 2.5 and 25 µmol/l for other experiments) and a control group (cultured with an equal volume of culture medium containing 0.1% DMSO).

MTT assay

For the MTT assays, 4×103 cells were seeded into each well of 96-well plates. Following conventional culture for 24 h, 200 µl of the different concentrations of ouabain were added into each well and the cells were cultured for another 24 h at 37°C. In the control group, the cells were cultured in 200 µl of culture medium containing 0.1% DMSO only. Following culture, 10 µl of 5 mg/ml MTT was added to the cells in each well and incubated for 4 h. Subsequently, 150 µl of DMSO (150 µl) was added for 10 min and the plates were positioned in a microplate autoreader (Thermo Fisher Scientific, Inc.) The optical density at 490 nm wavelength was read. On the basis of the optical density (A value), cell viability was calculated as follows: Cell viability=average A value of ouabain-treated cells/average A value of control ×100%. The half maximal inhibitory concentration (IC50) value was calculated as the concentration required for 50% inhibition of cell growth.

Digital holographic microscopy (DHM) assay

The DHM (HoloMonitor™ M4; Phase Holographic Imaging AB, Lund, Sweden) was used to record the 3D structure of adherent cells via interfering wave front induction when exposed to the 0.8 mW HeNe laser (633 nm). The DHM was based on measurements of how the cells shift light, which passes through the cells without any labeling or staining. The cells were plated in 6-well plates at 1×105/ml and cultured for 24 h, following which different concentrations of ouabain were added into each well prior to being moved to the DHM. This was placed in an incubator and was used to capture time-lapse images of the 6-well plates at 5 min intervals for 24 h. For each sample, a region for imaging was randomly selected and changes in cell number were analyzed using HoloStudio 2.6.2 software (Holographic Imaging AB). In addition, 10 cells were randomly selected per well to perform cell motion tracking, and cell motility was determined as the distance of cell movement throughout the 24 h of time-lapse video.

Protein extraction and western blot analysis

Following treatment with 0.05, 0.5, 2.5 and 25 µmol/l of ouabain for 24 h, the cells were rinsed in ice-cold PBS three times, collected with a cell scraper, and lysed in lysis buffer containing 50 mmol/l Tris-HCl (pH 7.2), 250 mmol/l NaCl, 0.1% NP-40, 2 mmol/l EDTA, 10% glycerol, 1 mmol/l PMSF, 5 µg/ml aprotinin and 5 µg/ml leupeptin on ice. The concentrations of the proteins of interest were quantified using the BCA method. Protein samples (40 µg) of each group were separated by 10% polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes, which were blocked at room temperature by 5% nonfat milk for 1 h. The membranes were then incubated with primary antibodies including Akt (ab179463, 1:1,000; Abcam, Cambridge, MA, USA), p-Akt (ab81283, 1:1,000; Abcam, Cambridge, MA, USA), mTOR (ab32028, 1:1,000; Abcam), p-mTOR (ab109268, 1:1,000; Abcam) and HIF-1α (ab51608, 1:1,000; Abcam) overnight at 4°C and were subsequently incubated with secondary antibody (anti-rabbit IgG; 5210-0174; 1:5,000; KPL, Inc., Gaithersburg, MD, USA) for 2 h at room temperature. β-actin was used as the internal control for protein loading.

High-content screening (HCS) assay

The cells were seeded in 96-well plates at 2×105/well, cultured for 24 h, and treated with different concentrations of ouabain added into each well. The cells were then fixed with 4% paraformaldehyde and permeabilized with 0.25% Triton-X 100. The fixed cells were nonspecifically blocked in 5% nonfat milk for 1 h and incubated with primary antibodies (Akt, p-Akt, mTOR, p-mTOR, and HIF-1α) at 1:1,000 dilution overnight at 4°C. Following incubation, the cells were stained with FITC-labeled anti-rabbit IgG secondary antibody (5230–0298; 1:200 dilution; KPL, Inc., Gaithersburg, MD, USA) for 1 h at room temperature, and 1 g/ml of DAPI for 10 min. The immunofluorescence of the stained cells was quantified using the HCA cell analyzer 2200 (GE Healthcare Life Sciences, Chalfont, UK).

Statistical analysis

SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL, ISA) was used for data analysis. All data are expressed as the mean ± standard deviation and were analyzed using one-way analysis of variance followed Tukey's post hoc analysis. P<0.05 was considered to indicate a statistically significant difference.

Results

Ouabain suppresses the viability of U-87MG cells

To assess the effect of ouabain on U-87MG cells, the cultured U-87MG cells were exposed to different concentrations of ouabain for 24 h. The U-87MG cells in the control group exhibited orderly shapes, well-defined borders and satisfactory diopter. By contrast, the cells treated with increasing concentrations of ouabain gradually shrunk, and exhibited poorly defined margins and irregular shapes, with cell death observed (Fig. 1A-G). As shown in Fig. 2A, the control cells grew into clusters with a normal morphology, whereas the cells treated with ouabain exhibited increasing shrinkage as the concentration of ouabain increased. The results of the MTT assay indicated that the viability of cells treated with ouabain were significantly decreased and in a dose-dependent manner, compared with those in the control group. The IC50 of ouabain treatment for 24 h was 0.45 µmol/l (Fig. 2B). The analysis of cell numbers suggested that ouabain treatment decreased the number of cells in a dose-dependent manner, which was in line with the morphological changes and the MTT results (Fig. 2C).

Figure 1.

Phase contrast microscopy of morphological changes in U-87MG cells treated with ouabain. Cells were treated with different concentrations of ouabain for 24 h. (A) Control group. (B) 0.05 µmol/l ouabain, (C) 0.25 µmol/l ouabain, (D) 0.5 µmol/l ouabain, (E) 2.5 µmol/l ouabain (F) 5 µmol/l ouabain and (G) 25 µmol/l ouabain. Scale bar=200 µm.

Figure 2.

Ouabain suppresses U-87MG cell growth. Cells were incubated with different concentrations of ouabain for 24 h. (A) Time-lapse images were captured using a digital hologram microscope. Scale bar=100 µm. (B) Cell viability was determined as the percentage of cells, compared with those in the control culture. (C) Cell numbers were analyzed using HoloStudio 2.6.2 software. **P<0.01, vs. control group.

Ouabain inhibits the motility of U-87MG cells

In order to investigate whether U-87MG cell motility was reduced under ouabain treatment, compared with controls, time-lapse videos were used to assess real-time cell motility, and cell displacement in the control and under different concentrations of ouabain were tracked. The cell motion tracking indicated that, following treatment with ouabain for 24 h, the movement range of U-87MG cells was decreased as the concentration of ouabain increased, and the routes of selected cells were irregular and multidirectional (Fig. 3A). Compared with the control (919±79 µm), the migration ability of the U-87MG cells in 0.5, 2.5 and 25 µmol/l ouabain treatment groups were suppressed in a dose-dependent manner (0.5 µmol/l, 620±115 µm; 2.5 µmol/l, 498±107 µm; 25 µmol/l, 387±42 µm; P<0.01; Fig. 3B).

Figure 3.

Inhibition of U-87MG cell motility is induced by ouabain. Cells were treated with the indicated concentrations of ouabain for 24 h. (A) Motion tracking of selected cells in the imaging area was performed using HoloStudio 2.6.2 software. The curved colored lines represent the moving path of selected wells during 24 h treatment and the yellow cross dots indicate cell nuclei in the imaging field. (B) Cell motility was measured as the distance of cell movement throughout the 24 h time-lapse video and analyzed using HoloStudio 2.6.2 software. Scale bar=100 µm. **P<0.01, vs. control group.

Ouabain affects the expression of Akt/mTOR signaling pathway proteins

It has been shown that the survival and proliferation of glioma cells can be enhanced by activation of the Akt/mTOR signaling pathway, which has been targeted for glioma treatment (10). To obtain additional evidence for the ouabain-inhibited viability and motility of U-87MG cells, the expression of Akt/mTOR signaling pathway regulators were analyzed using western blot analysis and HCS. As shown in Fig. 4, the protein expression levels of p-Akt and HIF-1α in the 0.05 µmol/l ouabain-treated group was significantly altered, compared with that in the control group (p-Akt, 1.30±0.02, vs. 0.96±0.04, P<0.01; HIF-1α, 1.32±0.24, vs. 1.06±0.16, P<0.05;), whereas that of mTOR and p-mTOR decreased rapidly (mTOR, 0.95±0.04, vs. 1.31±0.13, P<0.05; p-mTOR, 0.36±0.04, vs. 1.16±0.04, P<0.01). Treatment with 0.5 µmol/l ouabain reduced only the expression of p-Akt (0.15±0.04, vs. 0.96±0.04, P<0.01). In addition, the expression levels of Akt, mTOR, p-mTOR and HIF-1α were decreased by 2.5 and 25 µmol/l ouabain: p-Akt, 0.21±0.02 and 0.48±0.02, vs. 0.96±0.04; mTOR, 0.60±0.03 and 0.50±0.01, vs. 1.31±0.14; p-mTOR, 0.45±0.04 and 0.43±0.03, vs. 1.16±0.04; HIF-1α, 0.28±0.05 and 0.20±0.04, vs. 1.06±0.16 (P<0.05 or P<0.01). However, no significant differences were found in the expression of Akt following treatment with ouabain (P>0.05). These results were corroborated by HCS assays (Fig. 5). Therefore, it was hypothesized that ouabain mediated the suppression of U-87MG cell viability and motility via downregulating proteins of the Akt/mTOR signaling pathway.

Figure 4.

Changes in expression levels of Akt, p-Akt, mTOR, p-mTOR and HIF-1α in U-87MG cells are induced by ouabain. Cells were treated with the different concentrations of ouabain for 24 h, following which protein expression was analyzed using western blot analysis and quantified in relation to β-actin. *P<0.05 and **P<0.01, vs. control group. mTOR, mammalian target of rapamycin; p-, phosphorylated; HIF-1α, hypoxia inducible factor-1α.

Figure 5.

High content screening analyses of the changes in protein levels treated with ouabain. U-87MG cells were treated with the different concentrations of ouabain for 24 h and fluorescence images were captured. Scale bar=50 µm. mTOR, mammalian target of rapamycin; p-, phosphorylated; HIF-1α, hypoxia inducible factor-1α.

Discussion

There has been important progress in therapeutic strategies for gliomas in previous decades, as one of the most malignant types of brain tumor with high relapse and mortality rates. In the present study, ouabain intervention of glioma U-87MG cells was performed for the experimental investigation of therapeutic strategies for glioma, as U-87MG cells are more susceptible to cardiac glycosides, and ouabain can cross the blood brain barrier as a liquid, soluble cardiac glycoside.

Na+/K+-ATPase comprises an α subunit and β subunit, and the α subunit, which is essential in the transport activity of Na+/K+-ATPase, contains multiple binding sites of ATP and the enzyme inhibitor ouabain (11). Increasing evidence suggests that Na+/K+-ATPase is essential in the regulation of ion homeostasis and formation of the pathogenesis of glioma. Ahmed et al (12) reported that the inhibition of Na+/K+-ATPase regulated cell adhesion and migration, inhibited intracellular PKC and the NF-κB signaling pathway, and consequently resulted in the apoptosis of tumor cells. Additionally, Lin et al (13) found that ouabain inhibited the α-subunit activity of Na+/K+-ATPase, suppressed tumor cell growth, and eventually caused tumor cell death. The present study revealed that ouabain intervention inhibited U-87MG cell viability and cell motility in a dose-dependent manner, suggesting that ouabain promoted the apoptosis of U87-MG cells, which may be associated with alterations in certain intracellular signaling pathways.

In previous years, there has been an improved understanding of the role of Na+/K+-ATPase in multiple signaling pathways, including Akt/mTOR, Ras and PKC, resulting in the promotion of tumor invasion and metastasis (14). Notably, the Akt/mTOR signaling pathway is crucial for tumor progression according to the regulation of cell survival, proliferation, invasion and stem cell function (15). The upregulation of Akt/mTOR can directly or indirectly inhibit the phosphorylation of B-cell lymphoma 2-associated X protein, caspase-9 and other apoptosis-associated proteins, which attenuates apoptosis and leads to the deterioration of physiological functions (16). Liu et al (17) confirmed the effect of inhibition of the Akt/mTOR pathway against apoptosis in glioma; the pharmacological suppression of Akt/mTOR and their phosphorylation upregulates downstream proteins correlated with apoptosis, inducing an increase in the apoptosis of tumor cells.

Previous studies have confirmed that ouabain depresses the phosphorylation of Akt and mTOR via regulating phosphoinositide 3-kinase (PI3K), Ras and PKC signaling pathways, which causes cell growth depression and the enhancement of apoptosis (13). In the present study, it was found that the phosphorylation of Akt and mTOR significantly reduced cell viability, survival rate and cell mobility when treated with 2.5 and 25 µmol/l of ouabain, which confirmed that the antitumor property of ouabain involved the alteration of certain intracellular signaling pathways.

The overexpression of HIF-1α has been reported in several types of human tumor and metastasis, including glioma, which is closely associated with tumor invasion and metastasis, resistance to chemotherapy and radiotherapy, and poor prognosis (18). As an important regulator in hypoxic microenvironments, resulting from insufficient oxygen and nutrient supply for rapidly growing tumors, the activation of HIF-1α promotes tumor adaption to hypoxia through the promotion of cell survival, motility and angiogenesis (19,20). Soeda et al (21) demonstrated that the hypoxic induction of HIF-1α facilitated the self-renewal and proliferation of glioma stem cells, and maintained glioma stem cells in an undifferentiated state with multilineage potential. This assisted in glioma progression and metastasis.

In addition, previous studies have documented that the Akt/mTOR pathway is associated with hypoxia signaling transduction. The phosphorylation of Akt and mTOR can intensify the hypoxic induction of HIF-1α at the translational level, and promotes the stabilization and activation of HIF-1α, which regulates intracellular glucose utilization and angiogenesis, eventually promoting the growth of tumor cells (19,22). García-Maceira and Mateo demonstrated that inhibiting the phosphorylation of Akt and mTOR occurred with loss of the expression of HIF-1α, whereas inhibition of the Akt/mTOR pathway decreased the translation of HIF-1α and ultimately led to apoptosis of tumor cells (23). Consistently, the present study demonstrated that the downregulation of HIF-1α was simultaneous with the reduced phosphorylation of Akt and mTOR at high concentrations of ouabain (2.5 and 25 µmol/l), suggesting that the regulation of HIF-1α by the Akt/mTOR pathway was involved in tumor suppressive effect of ouabain.

In conclusion, the data obtained in the present study suggested that high concentrations of ouabain may depress human glioma U-87MG cell growth, attenuate cell mobility and lead to apoptosis via inhibiting the intracellular Akt/mTOR pathway and associated HIF-1α. These data identify ouabain as a potential target for the treatment of glioma in the future.